Randomized trial of bone marrow versus lenograstim-primed blood cell allogeneic transplantation in patients with early-stage leukemia: a report from the Société Française de Greffe de Moelle.

PURPOSE To compare hematologic recovery in patients receiving allogeneic blood cell transplantation (BCT) with those receiving allogeneic bone marrow transplantation (BMT). PATIENTS AND METHODS One hundred eleven patients with leukemia in the early stages and with HLA-matched sibling donors were randomized in this study. One hundred one underwent transplantation. Standard procedures for collection and transplantation were used. Patients did not receive prophylactic granulocyte colony-stimulating factor after undergoing transplantation. In addition to clinical end points being established, a prospective and comparative economic evaluation of the first 6 months after transplantation was performed. RESULTS Groups were balanced for patient, donor, and transplant characteristics. Blood cell collection led to the collection of a higher number of CD34(+) and CD3(+) cells than did bone marrow collection (P < 10(-6)) without reported side effects for the donor. Patients in the BCT group reached platelet counts of 25 and 50 x 10(9) platelets/L 8 and 11 days earlier than did the BMT group (P < 10(-4) and P < 10(-5)), respectively. This resulted in fewer platelet transfusions during the first 180 days after transplantation (P =.002) for the former group. The time to reach neutrophil counts of 0.5 and 1 x 10(9) neutrophils/L was 6 and 7 days shorter, respectively, in the BCT group than in the BMT group (P < 10(-5)). This quicker hematologic recovery was associated with a shorter length of hospitalization and a decrease in total cost of procedure during the first 6 months. CONCLUSION This study establishes that allogeneic BCT results in quicker hematologic recovery but is associated with a higher occurrence of chronic graft-versus-host disease.

[1]  J Crowley,et al.  Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. , 1999, Statistics in medicine.

[2]  F. Aversa,et al.  Spontaneous rupture of spleen during peripheral blood stem-cell mobilisation in a healthy donor , 1999, The Lancet.

[3]  J. Blache,et al.  OPTIMIZATION OF PERIPHERAL BLOOD STEM CELL COLLECTION BY LEUKOPHERESIS , 1999, International Journal of Technology Assessment in Health Care.

[4]  M. Beksac,et al.  A retrospective comparison of allogeneic peripheral blood stem cell and bone marrow transplantation results from a single center: a focus on the incidence of graft-vs.-host disease and relapse. , 1999, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[5]  D. Blaise,et al.  Mobilisation of healthy donors with lenograstim and transplantation of HLA-genoidentical blood progenitors in 54 patients with hematological malignancies: a pilot study , 1998, Bone Marrow Transplantation.

[6]  N. Schmitz,et al.  Allogeneic bone marrow transplantation vs filgrastim-mobilised peripheral blood progenitor cell transplantation in patients with early leukaemia: first results of a randomised multicentre trial of the European Group for Blood and Marrow Transplantation , 1998, Bone Marrow Transplantation.

[7]  K. Sullivan,et al.  Allogeneic peripheral blood stem cell transplantation may be associated with a high risk of chronic graft-versus-host disease. , 1997, Blood.

[8]  N. Schmitz,et al.  Allogeneic peripheral blood progenitor cell transplantation in a murine model : Evidence for an improved graft-versus-leukemia effect , 1997 .

[9]  N. Schmitz,et al.  Allogeneic blood stem cell transplantation: considerations for donors. , 1997, Blood.

[10]  D. Blaise,et al.  Early establishment of chimerism in the B and T lymphoid lineages after transplantation of allogeneic mobilized blood cells in leukemic patients. , 1997, Transplantation.

[11]  D. Blaise,et al.  Early and fatal immune haemolysis after so-called ‘minor’ ABO-incompatible peripheral blood stem cell allotransplantation , 1997, Bone Marrow Transplantation.

[12]  D. Blaise,et al.  Peripheral Blood Stem Cell and Bone Marrow Transplantation for Solid Tumors and Lymphomas: Hematologic Recovery and Costs: A Randomized, Controlled Trial , 1997, Annals of Internal Medicine.

[13]  A. Gratwohl,et al.  Blood and marrow transplantation activity in Europe 1995 , 1997, Bone Marrow Transplantation.

[14]  J. Garcia-conde,et al.  High incidence of chronic graft versus host disease after allogeneic peripheral blood progenitor cell transplantation. The Spanish Group of Allo-PBPCT. , 1997, Haematologica.

[15]  R. Storb,et al.  Allogeneic peripheral blood stem cell transplantation in patients with advanced hematologic malignancies: a retrospective comparison with marrow transplantation. , 1996, Blood.

[16]  D. Feeny,et al.  Economic evaluation of allogeneic bone marrow transplantation: a rudimentary model to generate estimates for the timely formulation of clinical policy. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  A. Santoro,et al.  High incidence of chronic GVHD after primary allogeneic peripheral blood stem cell transplantation in patients with hematologic malignancies. , 1996, Bone marrow transplantation.

[18]  N. Schmitz,et al.  Randomised trial of filgrastim-mobilised peripheral blood progenitor cell transplantation versus autologous bone-marrow transplantation in lymphoma patients , 1996, The Lancet.

[19]  J. Ferrara,et al.  Pretreatment of donor mice with granulocyte colony-stimulating factor polarizes donor T lymphocytes toward type-2 cytokine production and reduces severity of experimental graft-versus-host disease. , 1995, Blood.

[20]  R. Storb,et al.  Factors that influence collection and engraftment of autologous peripheral-blood stem cells. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  R. Storb,et al.  Transplantation of allogeneic peripheral blood stem cells mobilized by recombinant human granulocyte colony-stimulating factor , 1995 .

[22]  A. Deisseroth,et al.  Allogeneic blood stem cell transplantation for refractory leukemia and lymphoma: Potential advantage of blood over marrow allografts , 1995 .

[23]  N. Schmitz,et al.  Primary transplantation of allogeneic peripheral blood progenitor cells mobilized by filgrastim (granulocyte colony-stimulating factor) , 1995, Blood.

[24]  D. Blaise,et al.  Comparison of G-CSF-primed peripheral blood progenitor cells and bone marrow auto transplantation: clinical assessment and cost-effectiveness. , 1994, Bone Marrow Transplantation.

[25]  M. Pepe,et al.  Summarizing data on survival, relapse, and chronic graft‐versus‐host disease after bone marrow transplantation: motivation for and description of new methods , 1993, British journal of haematology.

[26]  S. Goodman,et al.  Factors influencing third party payer costs for allogeneic BMT. , 1993, Bone marrow transplantation.

[27]  J. Reiffers,et al.  Comparative cost of allogeneic or autologous bone marrow transplantation and chemotherapy in patients with acute myeloid leukaemia in first remission. , 1992, Bone marrow transplantation.

[28]  J. Bergerat,et al.  The TAM regimen prior to allogeneic and autologous bone marrow transplantation for high-risk acute lymphoblastic leukemias: a cooperative study of 62 patients. , 1991, Bone marrow transplantation.

[29]  D. Jolly,et al.  Cost of allogeneic bone marrow transplantation in four diseases. , 1989, Health policy.

[30]  J. Doroshow,et al.  Total body irradiation and high-dose etoposide: a new preparatory regimen for bone marrow transplantation in patients with advanced hematologic malignancies [published erratum appears in Blood 1987 Jun;69(6):1789] , 1987 .

[31]  H. Deeg,et al.  Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. , 1986, The New England journal of medicine.

[32]  J R Anderson,et al.  Analysis of survival by tumor response. , 1983, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  J. Eisenberg New drugs and clinical economics: analysis of cost effectiveness in the assessment of pharmaceutical innovations. , 1984, Reviews of infectious diseases.

[34]  Jean E. Sanders,et al.  Marrow harvesting from normal donors. , 1984, Blood.

[35]  R. Brookmeyer,et al.  Marrow transplantation for acute nonlymphocytic leukemia after treatment with busulfan and cyclophosphamide. , 1983, The New England journal of medicine.

[36]  S. Finkler The distinction between cost and charges. , 1982, Annals of internal medicine.

[37]  K. Sullivan,et al.  Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. , 1980, The American journal of medicine.

[38]  R. Powles,et al.  COST OF BONE-MARROW TRANSPLANTS IN ACUTE MYELOID LEUKÆMIA , 1980, The Lancet.

[39]  R Storb,et al.  Bone-marrow transplantation (first of two parts). , 1975, The New England journal of medicine.

[40]  P. Neiman,et al.  CLINICAL MANIFESTATIONS OF GRAFT‐VERSUS-HOST DISEASE IN HUMAN RECIPIENTS OF MARROW FROM HL‐A-MATCHED SIBLING DONOR,S , 1974, Transplantation.

[41]  N. Mantel Evaluation of survival data and two new rank order statistics arising in its consideration. , 1966, Cancer chemotherapy reports.